Independent review report to Johnson Matthey
Plc
Report on the condensed consolidated interim financial
statements
Our conclusion
We have reviewed Johnson Matthey
Plc's condensed consolidated interim financial statements (the
"interim financial statements") in the half year results of Johnson
Matthey Plc for the 6 month period ended 30th September
2024 (the "period").
Based on our review, nothing has
come to our attention that causes us to believe that the interim
financial statements are not prepared, in all material respects, in
accordance with UK adopted International Accounting Standard 34,
'Interim Financial Reporting' and the Disclosure Guidance and
Transparency Rules sourcebook of the United Kingdom's Financial
Conduct Authority.
The interim financial statements
comprise:
·
the Condensed Consolidated Statement of Financial
Position as at 30th September 2024;
·
the Condensed Consolidated Income Statement and
Condensed Consolidated Statement of Total Comprehensive Income for
the period then ended;
·
the Condensed Consolidated Statement of Cash
Flows for the period then ended;
·
the Condensed Consolidated Statement of Changes
in Equity for the period then ended; and
·
the explanatory notes to the interim financial
statements.
The interim financial statements
included in the half year results of Johnson Matthey Plc have been
prepared in accordance with UK adopted International Accounting
Standard 34, 'Interim Financial Reporting' and the Disclosure
Guidance and Transparency Rules sourcebook of the United Kingdom's
Financial Conduct Authority.
Basis for conclusion
We conducted our review in
accordance with International Standard on Review Engagements (UK)
2410, 'Review of Interim Financial Information Performed by the
Independent Auditor of the Entity' issued by the Financial
Reporting Council for use in the United Kingdom ("ISRE (UK) 2410").
A review of interim financial information consists of making
enquiries, primarily of persons responsible for financial and
accounting matters, and applying analytical and other review
procedures.
A review is substantially less in
scope than an audit conducted in accordance with International
Standards on Auditing (UK) and, consequently, does not enable us to
obtain assurance that we would become aware of all significant
matters that might be identified in an audit. Accordingly, we do
not express an audit opinion.
We have read the other information
contained in the half year results and considered whether it
contains any apparent misstatements or material inconsistencies
with the information in the interim financial
statements.
Conclusions relating to going concern
Based on our review procedures,
which are less extensive than those performed in an audit as
described in the Basis for conclusion section of this report,
nothing has come to our attention to suggest that the directors
have inappropriately adopted the going concern basis of accounting
or that the directors have identified material uncertainties
relating to going concern that are not appropriately disclosed.
This conclusion is based on the review procedures performed in
accordance with ISRE (UK) 2410. However, future events or
conditions may cause the group to cease to continue as a going
concern.
Responsibilities for the interim financial statements and the
review
Our responsibilities and those of the
directors
The half year results, including
the interim financial statements, is the responsibility of, and has
been approved by the directors. The directors are responsible for
preparing the half year results in accordance with the Disclosure
Guidance and Transparency Rules sourcebook of the United Kingdom's
Financial Conduct Authority. In preparing the half year results,
including the interim financial statements, the directors are
responsible for assessing the group's ability to continue as a
going concern, disclosing, as applicable, matters related to going
concern and using the going concern basis of accounting unless the
directors either intend to liquidate the group or to cease
operations, or have no realistic alternative but to do
so.
Our responsibility is to express a
conclusion on the interim financial statements in the half year
results based on our review. Our conclusion, including our
Conclusions relating to going concern, is based on procedures that
are less extensive than audit procedures, as described in the Basis
for conclusion paragraph of this report. This report, including the
conclusion, has been prepared for and only for the company for the
purpose of complying with the Disclosure Guidance and Transparency
Rules sourcebook of the United Kingdom's Financial Conduct
Authority and for no other purpose. We do not, in giving this
conclusion, accept or assume responsibility for any other purpose
or to any other person to whom this report is shown or into whose
hands it may come save where expressly agreed by our prior consent
in writing.
PricewaterhouseCoopers
LLP
Chartered Accountants
London
26th November
2024
|
|
|
|
1
|
Basis of preparation and statement of
compliance
|
These condensed consolidated
interim financial statements for the half-year reporting period
ended 30th September 2024 (the 'condensed consolidated
accounts') have been prepared in accordance with UK-adopted
International Accounting Standard 34, 'Interim Financial Reporting' and the
Disclosure Guidance and Transparency Rules sourcebook of the UK's
Financial Conduct Authority. The accounting policies, estimates and
judgements applied in the condensed consolidated accounts are
consistent with the accounting policies, estimates and judgements
applied by the group in its consolidated accounts as at, and for
the year ended, 31st March 2024, with the exception of
the adoption of amended accounting policies and standards as
explained below.
These condensed consolidated
accounts do not constitute statutory accounts within the meaning of
Section 435 of the Companies Act 2006. They do not include all of
the notes of the type normally included in an annual financial
report. Accordingly, the condensed consolidated accounts should be
read in conjunction with the annual report for the year ended
31st March 2024, which has been prepared in accordance
with UK-adopted International Accounting Standards (IAS) and with
the requirements of the Companies Act 2006.
Information in respect of the year
ended 31st March 2024 is derived from the company's
statutory accounts for that year which have been delivered to the
Registrar of Companies. The auditor's report on those statutory
accounts was unqualified, did not include a reference to any
matters to which the auditor drew attention by way of emphasis
without qualifying its report and did not contain any statement
under Section 498 (2) or Section 498 (3) of the Companies Act
2006.
The condensed consolidated
accounts are unaudited but have been reviewed by the auditors. They
were approved by the board of directors on 26th November
2024.
Going concern
The directors have reviewed the
base case scenario, and the severe but plausible downside case
scenario and have reasonable expectation that there are no material
uncertainties that cast doubt about the group's ability to continue
operating for at least twelve months from the date of approving
these half-yearly accounts.
As at 30th September
2024, the group maintains a strong balance sheet with around £1.6
billion of available cash and undrawn committed facilities. Cash
generation was positive during the period with free cash flow of
£347 million. Net debt has reduced by £168 million since
31st March 2024 to £783 million, driven by proceeds from
disposals. Net debt (including post tax pension deficits) to
underlying EBITDA, was below our target range at 1.4
times.
While inflation has been
decreasing and interest rates have started to fall, significant
headwinds remain due to ongoing global auto sector weakness,
persistent geopolitical tensions and political uncertainty in the
US. Despite these challenges, the group demonstrated resilience
during the period, with underlying operating profit (excluding the
impact of divestments) only modestly down. For the purposes of
assessing going concern, we have revisited our financial
projections using the latest forecasts for our base case scenario.
The base case scenario was stress tested to a severe but plausible
downside case which reflects lower demand across our markets to
account for significant disruption from external factors and a deep
recession.
Additionally, the group considered
scenarios including the impact from metal price volatility and
increases in the amount of metal that we would have to hold, along
with a slowdown in operations in China. We have also considered the
impact of a refinery shutdown for a prolonged period. Whilst the
combined impact would reduce profitability and EBITDA against our
latest forecast, our balance sheet would remain strong.
|
|
|
|
1
|
Basis of preparation and statement of compliance
(continued)
|
Going concern (continued)
The group has a robust funding
position comprising a range of long-term debt and a £1 billion five
year committed revolving credit facility maturing in March 2027
which was entirely undrawn at 30th September 2024. There
was £456 million of cash held in money market funds. Of the
existing loans, around £340 million of term debt matures in the
period to December 2025. In October 2024, the group refinanced
around £300 million of term debt with a US Private Placement
issuance, with funds scheduled for drawdown in December 2024. We
have excluded this refinancing from our going concern modelling. As
a long time, highly rated issuer in the US private placement
market, the group expects to be able to access additional funding
in its existing markets should it need to. The group also has a
number of additional sources of funding available including
uncommitted lease facilities that support precious metal funding.
Whilst we would fully expect to be able to utilise the metal lease
facilities, they are excluded from our going concern
modelling.
Under all scenarios above, the
group has sufficient headroom against committed facilities and key
financial covenants are not in breach during the going concern
period. There remain risks to the group including more extreme
economic outcomes. Against these, the group has a range of levers
which it could utilise to protect headroom including reducing
capital expenditure and future dividend distributions.
The directors are therefore of the
opinion that the group has adequate resources to fund its
operations for at least twelve months from the date of approving
these half year accounts and so determine that it is appropriate to
prepare the accounts on a going concern basis.
Non-GAAP measures
The group uses various measures to
manage its business which are not defined by generally accepted
accounting principles (GAAP). The group's management believes these
measures provide valuable additional information to users of the
accounts in understanding the group's performance. The group's
non-GAAP measures are defined and reconciled to GAAP measures in
note 17.
Amended standards adopted by the group
The IASB has issued the following
amendments, which have been endorsed by the UK Endorsement Board,
for annual periods beginning on or after 1st January
2024:
- Amendments to IAS 1, Presentation of Financial
Statements;
- Amendments to IFRS 16, Leases;
- Amendments to IAS 7, Statement of Cash Flows and IFRS 7,
Financial Instruments:
Disclosures relating to Supplier Finance
Arrangements
The new or amended standards and
interpretations above that are effective for the year ended
31st March 2025 have not had a material impact on the
group. The group has not early adopted any standard, amendment or
interpretation that was issued but is not yet effective.
|
|
|
|
|
|
|
|
|
|
|
2
|
Segmental information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, sales and underlying operating profit by
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean Air - provides catalysts for
emission control after-treatment systems used in light and heavy
duty vehicles powered by internal combustion engines.
PGM Services - enables the energy
transition through providing circular solutions as demand for
scarce critical materials increases. Provides a strategic service
to the group, supporting the other segments with security of metal
supply, and manufactures value-add PGM products.
Catalyst Technologies - licenses
process technology and supplies catalysts to the chemical and
energy sectors, enabling the decarbonisation of fuels and chemical
value chains.
Hydrogen Technologies - provides
components across the value chain for fuel cells and electrolysers
including catalyst coated membranes and membrane electrode
assemblies.
Value Businesses - a portfolio of
businesses managed to drive shareholder value from activities
considered to be non-core to the group. The disposal of the Value
Businesses portfolio concluded during the period, with Battery
Systems (sold on 30th April 2024), Medical Device
Components (sold on 1st July 2024) and the land and
buildings of our previous Battery Materials business in Poland
(sold on 24th July 2024). Refer to note 11 for further
details. Additionally, included in our prior period comparatives is
Diagnostic Services (sold on 29th September
2023).
The Group Leadership Team (the
chief operating decision maker as defined by IFRS 8, Operating Segments) monitors the
results of these operating businesses to assess performance and
make decisions about the allocation of resources. Each operating
business is represented by a member of the Group Leadership Team.
These operating businesses represent the group's reportable
segments and their principal activities are described on pages 18
to 25 of the 2024 Annual Report. The performance of the group's
operating businesses is assessed on sales and underlying operating
profit (see note 17). Sales between segments are made at market
prices, taking into account the volumes involved.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
Segmental information (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30th September
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Corporate
|
Eliminations
|
Total
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from external
customers
|
2,013
|
3,199
|
346
|
24
|
50
|
-
|
-
|
5,632
|
|
|
Inter-segment revenue
|
-
|
776
|
9
|
-
|
-
|
-
|
(785)
|
-
|
|
|
Revenue
|
2,013
|
3,975
|
355
|
24
|
50
|
-
|
(785)
|
5,632
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External
sales1
|
1,165
|
173
|
328
|
20
|
36
|
-
|
-
|
1,722
|
|
|
Inter-segment sales
|
-
|
34
|
8
|
-
|
-
|
-
|
(42)
|
-
|
|
|
Sales1
|
1,165
|
207
|
336
|
20
|
36
|
-
|
(42)
|
1,722
|
|
|
Underlying operating profit1
|
121
|
51
|
50
|
(26)
|
2
|
(42)
|
-
|
156
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30th September
2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Corporate
|
Eliminations
|
Total
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from external
customers
|
2,768
|
3,169
|
308
|
45
|
241
|
-
|
-
|
6,531
|
|
|
Inter-segment revenue
|
-
|
1,364
|
11
|
-
|
-
|
-
|
(1,375)
|
-
|
|
|
Revenue
|
2,768
|
4,533
|
319
|
45
|
241
|
-
|
(1,375)
|
6,531
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External
sales1
|
1,286
|
182
|
272
|
37
|
190
|
-
|
-
|
1,967
|
|
|
Inter-segment sales
|
-
|
48
|
10
|
-
|
-
|
-
|
(58)
|
-
|
|
|
Sales1
|
1,286
|
230
|
282
|
37
|
190
|
-
|
(58)
|
1,967
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying operating profit1
|
124
|
78
|
35
|
(26)
|
14
|
(45)
|
-
|
180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Sales and underlying operating profit are non-GAAP measures
(see note 17 for reconciliation to GAAP measures). Sales excludes
the sale of precious metals. Underlying operating profit excludes
profit or loss on disposal of businesses, amortisation of acquired
intangibles and major impairment and restructuring
charges.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
Segmental information (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net assets by business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 30th September 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Corporate
|
Total
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segmental net assets
|
|
1,440
|
140
|
783
|
270
|
6
|
312
|
2,951
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net debt (see note 17)
|
|
|
|
|
|
|
(783)
|
|
|
Post-employment benefit net assets
and liabilities
|
|
|
|
|
141
|
|
|
Deferred tax net assets
|
|
|
|
|
125
|
|
|
Provisions and non-current other
payables
|
|
|
|
|
(83)
|
|
|
Investments in
associates
|
|
|
|
|
69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net assets
|
|
|
|
|
|
|
|
2,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31st March 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Corporate
|
Total
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segmental net assets
|
|
1,351
|
38
|
718
|
271
|
178
|
449
|
3,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net debt (see note 17)
|
|
|
|
|
|
|
(946)
|
|
|
Post-employment benefit net assets
and liabilities
|
|
|
|
|
114
|
|
|
Deferred tax net assets
|
|
|
|
|
|
126
|
|
|
Provisions and non-current other
payables
|
|
|
|
|
|
(82)
|
|
|
Investments in
associates
|
|
|
|
|
|
71
|
|
|
Net assets held for
sale
|
|
|
|
|
|
92
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net assets
|
|
|
|
|
|
|
|
2,380
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Products and services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The group's principal products and
services by operating business and sub-business are disclosed in
the table below, together with information regarding performance
obligations and revenue recognition. Revenue is recognised by the
group as contractual performance obligations to customers are
completed.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sub-business
|
Primary industry
|
Principal products and services
|
Performance obligations
|
|
Revenue recognition
|
|
|
Clean Air
|
|
|
Light Duty Catalysts
|
Automotive
|
Catalysts for cars and other light
duty vehicles
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Heavy Duty Catalysts
|
Automotive
|
Catalysts for trucks, buses and
non-road equipment
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PGM Services
|
|
|
Platinum Group Metal
Services
|
Various
|
Platinum Group Metal refining and
recycling services
|
Over time
|
|
Based on output
|
|
|
|
|
|
|
|
|
|
|
Platinum Group Metal
trading
|
Point in time
|
|
On receipt of payment
|
|
|
|
|
|
|
|
|
|
|
Other precious metal
products
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
Platinum Group Metal chemical,
industrial products and catalyst
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
Catalyst Technologies
|
|
|
Catalysts
|
Chemicals / oil and gas /
sustainable fuels
|
Speciality catalysts and
additives
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing
|
Chemicals / oil and gas /
sustainable fuels
|
Process technology licences and
engineering design services
|
Over time / point in
time1
|
|
Based on costs incurred or at a
point in time1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hydrogen Technologies
|
|
|
Fuel Cells Technology
|
Various
|
Fuel cell catalyst coated
membranes
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Electrolysis Technology
|
Various
|
Electrolyser catalyst coated
membrane
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value Businesses
|
|
|
Other Markets (excluding
Diagnostic Services)
|
Various
|
Precious metal pastes and enamels,
battery systems and products found in devices used in medical
procedures
|
Point in time
|
|
On despatch or delivery
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostic Services
|
Oil and gas
|
Detection, diagnostic and
measurement solutions
|
Over time
|
|
Based on costs incurred
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Revenue recognition depends on whether the licence is
distinct in the context of the contract.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Metal revenue: Metal revenue
relates to the sales of precious metals to customers, either in
pure form or contained within a product. Metal revenue arises in
each of the reportable segments in the group. Metal revenue is
affected by fluctuations in the market prices of precious metals
and, in many cases, the value of precious metals is passed directly
on to customers. Given the high value of these metals this makes up
a significant proportion of revenue
|
|
|
|
|
|
|
|
3
|
Revenue (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from external customers by principal products and
services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30th September
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Total
|
|
|
|
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Metal
|
848
|
3,026
|
18
|
4
|
14
|
3,910
|
|
|
Heavy Duty Catalysts
|
364
|
-
|
-
|
-
|
-
|
364
|
|
|
Light Duty Catalysts
|
774
|
-
|
-
|
-
|
-
|
774
|
|
|
Platinum Group Metal
Services
|
-
|
173
|
-
|
-
|
-
|
173
|
|
|
Catalyst Technologies
|
-
|
-
|
328
|
-
|
-
|
328
|
|
|
Fuel Cells Technology
|
-
|
-
|
-
|
20
|
-
|
20
|
|
|
Battery Systems
|
-
|
-
|
-
|
-
|
15
|
15
|
|
|
Medical Device
Components
|
-
|
-
|
-
|
-
|
21
|
21
|
|
|
Other
|
27
|
-
|
-
|
-
|
-
|
27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
2,013
|
3,199
|
346
|
24
|
50
|
5,632
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30th September
2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Total
|
|
|
|
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Metal
|
|
|
|
|
1,482
|
2,987
|
36
|
8
|
51
|
4,564
|
|
|
Heavy Duty Catalysts
|
|
|
454
|
-
|
-
|
-
|
-
|
454
|
|
|
Light Duty Catalysts
|
|
|
812
|
-
|
-
|
-
|
-
|
812
|
|
|
Platinum Group Metal
Services
|
-
|
182
|
-
|
-
|
-
|
182
|
|
|
Catalyst Technologies
|
|
|
-
|
-
|
272
|
-
|
-
|
272
|
|
|
Fuel Cells Technology
|
|
|
|
|
-
|
-
|
-
|
37
|
-
|
37
|
|
|
Battery Systems
|
|
|
|
|
-
|
-
|
-
|
-
|
106
|
106
|
|
|
Diagnostic Services
|
|
|
|
|
-
|
-
|
-
|
-
|
37
|
37
|
|
|
Medical Device
Components
|
-
|
-
|
-
|
-
|
45
|
45
|
|
|
Other
|
|
|
|
|
20
|
-
|
-
|
-
|
2
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
2,768
|
3,169
|
308
|
45
|
241
|
6,531
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The contract receivables balance
at 30th September 2024 is £38 million (31st
March 2024: £56 million).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3
|
Revenue (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from external customers by point in time and over
time performance obligations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30th September
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Total
|
|
|
|
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue recognised at a point in
time
|
2,013
|
3,106
|
290
|
24
|
47
|
5,480
|
|
|
Revenue recognised over
time
|
-
|
93
|
56
|
-
|
3
|
152
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
2,013
|
3,199
|
346
|
24
|
50
|
5,632
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended 30th September
2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clean
|
PGM
|
Catalyst
|
Hydrogen
|
Value
|
|
|
|
|
|
|
|
|
|
Air
|
Services
|
Technologies
|
Technologies
|
Businesses
|
Total
|
|
|
|
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue recognised at a point in
time
|
2,768
|
3,081
|
255
|
45
|
213
|
6,362
|
|
|
Revenue recognised over
time
|
-
|
88
|
53
|
-
|
28
|
169
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
2,768
|
3,169
|
308
|
45
|
241
|
6,531
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
Operating profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months
ended
|
|
|
|
|
|
|
|
|
|
30.9.24
|
30.9.23
|
|
|
|
|
|
|
|
|
|
£
million
|
£
million
|
|
|
Operating profit is arrived at
after charging / (crediting):
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenditure charged to the income
statement
|
|
99
|
104
|
|
|
Less: External funding received -
from governments
|
|
(8)
|
(7)
|
|
|
Net research and development expenditure charged to the
income statement
|
|
91
|
97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation of:
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment
|
|
64
|
66
|
|
|
Right-of-use
assets
|
|
4
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
68
|
72
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortisation of:
|
|
|
|
|
|
|
|
|
|
|
Acquired
intangibles
|
2
|
2
|
|
|
Other intangible
assets
|
26
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortisation
|
|
28
|
23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit on disposal of businesses (note 11)
|
|
(484)
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment
|
|
|
5
|
-
|
|
|
Other intangible
assets
|
|
|
17
|
-
|
|
|
Inventories
|
|
|
1
|
2
|
|
|
Trade and other
receivables
|
|
|
-
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment losses
|
|
|
|
|
|
23
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring charges
|
|
40
|
30
|
|
|
Major impairment and restructuring charges
|
|
63
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit on disposal of businesses
On 30th April 2024, the
group completed the sale of Battery Systems, on 1st July
2024, the group completed the sale of its Medical Device Components
business. On 24th July 2024, the group completed the
sale of the land and buildings from our legacy Battery Materials
business in Poland, see note 11.
Major impairment and restructuring charges
Major impairment and restructuring
charges are shown separately on the face of the income statement
and excluded from underlying operating profit, see note
17.
Major impairments - the
group's impairment charge of £23 million includes a £17 million
impairment to the group's intangible assets following a review of
and subsequent changes to our IT operating model completed in June
2024. As a result of the review, certain IT assets have been
impaired. The remaining impairment charge is to production related
assets in Clean Air as the business continues to consolidate its
existing capacity into new and more efficient plants.
Major restructuring - the
group's transformation programme was launched in May 2022 and was
designed to drive increased competitiveness, improved execution
capability and create financial headroom to facilitate further
investment in high growth areas. Restructuring charges of £40
million have been recognised of which £19 million relates to
Johnson Matthey Global Solutions, IT transformation and running the
transformation programme, with £9 million other redundancy and
implementation costs. The remaining £12 million charge is related
to Clean Air's ongoing plant consolidation initiatives, of which
the majority is redundancy and exit costs.
The charge for taxation at the
half year ended 30th September 2024 is £70 million (1H
2023/24: £19 million), an effective tax rate of 12.4%. The tax
charge on underlying profit before tax was £29 million, an
effective tax rate of 21.9%, similar to the 22.0% in the half year
ended 30th September 2023.
The group is within the scope of
the OECD Pillar Two model rules. The group is in scope by virtue of
the parent company being tax resident in the UK. Pillar Two
legislation has been enacted in the UK, as well as several other
territories where the group operates, and became effective for the
group from the start of this financial period.
The group applies the exception to
recognising and disclosing information about deferred tax assets
and liabilities related to Pillar Two model rules, as provided in
the amendments to IAS 12 issued in May 2023.
Under the legislation, the group
is liable to pay a top-up tax for the difference between its Global
Anti-Base Erosion ('GloBE') effective tax rate per jurisdiction and
the 15% minimum rate. We have undertaken an assessment of the
group's potential to additional taxes under Pillar 2 and conclude
that, for the year ended 31st March 2025, the group is
expected to meet the exemptions in the Transitional Country by
Country Reporting ('CbCR') safe harbours in all tax jurisdictions
in which it operates, except for Bermuda and North Macedonia.
Income tax expense recognised in the consolidated statement of
profit and loss for the six months ended 30th September
2024 includes £1 million related to Pillar 2 income taxes. The
group will keep the position under review for future
periods.
We continue to monitor potential
impacts as further guidance is published, as territories implement
legislation to enact the rules, and as territories increase their
domestic Corporate Tax rate in response to the OECD Pillar 2
rules.
|
|
|
|
|
|
6
|
Earnings per ordinary share
|
|
|
|
|
|
|
|
|
|
|
|
Six months
ended
|
|
|
|
|
|
30.9.24
|
|
30.9.23
|
|
|
|
|
|
pence
|
|
pence
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
266.8
|
|
34.7
|
|
|
Diluted
|
|
|
266.4
|
|
34.6
|
|
|
|
|
|
|
|
|
|
|
Earnings per ordinary share have
been calculated by dividing profit for the period by the weighted
average number of shares in issue during the period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months
ended
|
|
|
Weighted average number of shares in issue
|
|
|
30.9.24
|
|
30.9.23
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
181,728,079
|
|
183,213,834
|
|
|
Dilution for long term incentive
plans
|
|
|
273,281
|
|
907,731
|
|
|
Diluted
|
|
|
182,001,360
|
|
184,121,565
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7
|
Dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
An interim dividend of 22.00 pence
per ordinary share has been proposed by the board which will be
paid on the 4th February 2025 to shareholders on the
register at the close of business on 6th December 2024.
The estimated amount to be paid is £38 million (1H 2023/24: £40
million) and has not been recognised in these accounts.
|
|
|
|
Six months
ended
|
|
|
|
|
|
30.9.24
|
|
30.9.23
|
|
|
|
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
2022/23 final ordinary dividend
paid ─ 55.00 pence per share
|
|
|
-
|
|
101
|
|
|
2023/24 final ordinary dividend
paid ─ 55.00 pence per share
|
|
|
101
|
|
-
|
|
|
Total dividends
|
|
|
101
|
|
101
|
|
On 3rd July 2024, the
company announced its intention to conduct a share buyback
programme for up to a maximum consideration of £250 million. The
first tranche of the share buyback programme of up to £125 million
commenced on 3rd July 2024 and completed on
23rd September 2024. On 24th September 2024,
the company commenced the second tranche of up to £125 million,
which will end no later than 24th January 2025. As at
30th September 2024, the company purchased 7,628,978
shares at a cost of £123 million. The residual balance of £127
million has been recognised within trade and other payables as at
30th September 2024.
|
|
|
|
|
|
|
|
|
|
|
8
|
Property, plant and equipment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
in
|
|
|
|
|
|
|
|
Freehold
land
|
Leasehold
|
Plant
and
|
the
course of
|
|
|
|
|
|
|
|
and
buildings
|
improvements
|
machinery
|
construction
|
Total
|
|
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
|
|
|
|
|
|
|
At 1st April
2024
|
591
|
23
|
2,143
|
515
|
3,272
|
|
Additions
|
-
|
-
|
6
|
143
|
149
|
|
Transfers from assets in the
course of construction
|
1
|
-
|
29
|
(30)
|
-
|
|
Disposals
|
-
|
-
|
(3)
|
-
|
(3)
|
|
Exchange adjustments
|
(15)
|
(1)
|
(51)
|
(5)
|
(72)
|
|
|
|
|
|
|
|
|
At 30th September
2024
|
577
|
22
|
2,124
|
623
|
3,346
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation and impairment
|
|
|
|
|
|
At 1st April
2024
|
290
|
12
|
1,522
|
12
|
1,836
|
|
Charge for the period
|
7
|
1
|
56
|
-
|
64
|
|
Impairment losses
|
-
|
-
|
5
|
1
|
6
|
|
Disposals
|
-
|
-
|
(3)
|
-
|
(3)
|
|
Exchange adjustments
|
(6)
|
(1)
|
(35)
|
-
|
(42)
|
|
|
|
|
|
|
|
|
At 30th September
2024
|
291
|
12
|
1,545
|
13
|
1,861
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying amount at 30th September
2024
|
286
|
10
|
579
|
610
|
1,485
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying amount at 1st
April 2024
|
301
|
11
|
621
|
503
|
1,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
|
Other intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer
contracts and relationships
|
Computer
software
|
Patents
trademarks and licences
|
Acquired
research and technology
|
Development expenditure
|
Total
|
|
|
|
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
|
|
|
|
|
|
|
|
At 1st April
2024
|
103
|
536
|
32
|
30
|
134
|
835
|
|
Additions
|
-
|
21
|
-
|
-
|
-
|
21
|
|
Exchange adjustments
|
(2)
|
(1)
|
(1)
|
(1)
|
-
|
(5)
|
|
|
|
|
|
|
|
|
|
At 30th September
2024
|
101
|
556
|
31
|
29
|
134
|
851
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated amortisation and impairment
|
|
|
|
|
|
|
At 1st April
2024
|
91
|
252
|
28
|
30
|
133
|
534
|
|
Charge for the period
|
2
|
25
|
1
|
-
|
-
|
28
|
|
Impairment losses (note
4)
|
-
|
17
|
-
|
-
|
-
|
17
|
|
Exchange adjustments
|
(2)
|
(1)
|
(2)
|
(1)
|
-
|
(6)
|
|
|
|
|
|
|
|
|
|
At 30th September
2024
|
91
|
293
|
27
|
29
|
133
|
573
|
|
|
|
|
|
|
|
|
|
Carrying amount at 30th September
2024
|
10
|
263
|
4
|
-
|
1
|
278
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying amount at 1st
April 2024
|
12
|
284
|
4
|
-
|
1
|
301
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10
|
Investments in associates
|
|
|
|
|
|
|
As part of the disposal of our
Health business, we received £75 million in the form of shares
which constitutes approximately 30% equity interest in the
re-branded business (Veranova). The group determined that it has
significant influence and therefore has equity accounted this stake
as an investment in associate.
|
|
|
|
|
|
|
|
|
|
|
Associates
|
|
|
|
|
|
|
|
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1st April
2024
|
|
|
|
|
71
|
|
Group's share of profits for the
period
|
|
|
|
|
2
|
|
Exchange adjustments
|
|
|
|
|
(4)
|
|
At 30th September 2024
|
|
|
|
|
69
|
|
|
|
|
|
|
|
11
|
Disposals
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Device Components
On 1st July 2024, the
group completed the sale of its Medical Device Components business
for an enterprise value of £555 million (£559 million on a debt
free basis after working capital adjustments). The business was
disclosed as a disposal group held for sale as at 31st
March 2024.
Battery Systems
On 30th April 2024, the
group completed the sale of its Battery Systems business for an
enterprise value of £14 million (£21 million on a debt free basis
after working capital adjustments). The business was disclosed as a
disposal group held for sale as at 31st March
2024.
Battery Materials Poland
On 24th July 2024, the
group completed the sale of the land and buildings of our previous
Battery Materials business in Poland for £26 million. This was
disclosed as assets held for sale as at 31st March
2024.
|
|
|
|
|
|
|
2024
|
|
2023
|
|
|
|
|
|
|
|
Medical Device
Components
|
Other
disposals
|
Total
|
|
Total
|
|
30th September
|
|
|
|
|
£
million
|
£
million
|
£
million
|
|
£
million
|
|
Proceeds
|
|
|
|
|
|
|
|
|
|
Cash consideration
|
|
|
|
555
|
30
|
585
|
|
47
|
|
Cash and cash equivalents
disposed
|
|
|
|
(10)
|
-
|
(10)
|
|
(3)
|
|
Net cash consideration
|
|
|
|
545
|
30
|
575
|
|
44
|
|
Disposal costs paid
|
|
|
|
(11)
|
(5)
|
(16)
|
|
(2)
|
|
Net cash inflow
|
|
|
|
534
|
25
|
559
|
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets and liabilities disposed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment
|
|
|
|
24
|
25
|
49
|
|
10
|
|
Right-of-use assets
|
|
|
|
4
|
-
|
4
|
|
9
|
|
Goodwill
|
|
|
|
3
|
-
|
3
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
|
|
8
|
20
|
28
|
|
5
|
|
Trade and other
receivables
|
|
|
|
18
|
20
|
38
|
|
32
|
|
Cash and cash
equivalents
|
|
|
|
10
|
-
|
10
|
|
3
|
|
Deferred tax
|
|
|
|
|
|
-
|
3
|
3
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
|
Trade and other
payables
|
|
|
|
(6)
|
(20)
|
(26)
|
|
(9)
|
|
Current income tax
liabilities
|
|
|
|
(1)
|
(1)
|
(2)
|
|
-
|
|
Lease liabilities
|
|
|
|
(4)
|
-
|
(4)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
|
|
|
|
Lease liabilities
|
|
|
|
-
|
(1)
|
(1)
|
|
(11)
|
|
Provisions
|
|
|
|
(1)
|
(1)
|
(2)
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net assets disposed
|
|
|
|
55
|
45
|
100
|
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11
|
Disposals (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
|
2023
|
|
|
|
|
|
|
|
Medical Device
Components
|
Other
disposals
|
Total
|
|
Total
|
|
30th September
|
|
|
|
|
£
million
|
£
million
|
£
million
|
|
£
million
|
|
Cash consideration
|
|
|
|
555
|
30
|
585
|
|
47
|
|
Deferred consideration
|
|
|
|
-
|
17
|
17
|
|
4
|
|
Working capital adjustments at
time of disposal
|
|
4
|
-
|
4
|
|
4
|
|
Less: carrying amount of net
assets sold
|
|
(55)
|
(45)
|
(100)
|
|
(42)
|
|
Less: disposal costs
|
|
(16)
|
(8)
|
(24)
|
|
(8)
|
|
Cumulative currency translation
gain recycled from other comprehensive income
|
|
-
|
2
|
2
|
|
(1)
|
|
Profit recognised in the income
statement
|
|
488
|
(4)
|
484
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disposal proceeds
During the period we received £3
million of proceeds relating to the Diagnostic Services disposal in
the prior year. This was recognised within profit on disposal in
the prior year.
|
|
|
12
|
Post-employment benefits
|
|
|
|
|
Background
The group operates a number of
post-employment benefit plans around the world, the forms and
benefits of which vary with conditions and practices in the
countries concerned. The major defined benefit plans are pension
plans and post-retirement medical plans in the UK and the
US.
|
Financial assumptions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The financial assumptions for the
major plans are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.9.24
|
31.3.24
|
|
|
|
|
|
|
|
UK plan
|
|
US
plans
|
|
UK
plan
|
|
US
plans
|
|
|
|
|
|
|
|
%
|
|
%
|
|
%
|
|
%
|
|
First year's rate of increase in
salaries
|
|
|
|
|
3.40
|
|
-
|
|
3.50
|
|
-
|
|
Ultimate rate of increase in
salaries
|
|
|
|
|
3.40
|
|
-
|
|
3.50
|
|
-
|
|
Rate of increase in pensions in
payment
|
|
|
|
|
2.80
|
|
-
|
|
2.90
|
|
-
|
|
Discount rate
|
|
|
|
|
5.10
|
|
4.90
|
|
4.90
|
|
5.20
|
|
Inflation
|
|
|
|
|
|
-
|
|
2.20
|
|
-
|
|
2.20
|
|
- UK Retail Prices Index
(RPI)
|
|
|
|
|
3.00
|
|
-
|
|
3.10
|
|
-
|
|
- UK Consumer Prices Index
(CPI)
|
|
|
|
|
2.65
|
|
-
|
|
2.75
|
|
-
|
|
Current medical benefits cost
trend rate
|
|
|
|
|
8.95
|
|
-
|
|
8.95
|
|
-
|
|
Ultimate medical benefits cost
trend rate
|
|
|
|
|
5.40
|
|
-
|
|
5.40
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The financial assumptions for the
other plans are reviewed and updated annually.
|
|
Financial information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Movements in the net
post-employment benefit assets and liabilities, including
reimbursement rights, were:
|
|
|
|
|
|
UK
|
|
UK
|
|
UK
post-
|
|
|
|
US
post-
|
|
|
|
|
|
|
|
|
|
pension -
|
|
pension -
|
|
retirement
|
|
|
|
retirement
|
|
|
|
|
|
|
|
|
|
legacy
|
|
cash
balance
|
|
medical
|
|
US
|
|
medical
|
|
|
|
|
|
|
|
|
|
section
|
|
section
|
|
benefits
|
|
pensions
|
|
benefits
|
|
Other
|
|
Total
|
|
|
|
|
|
£
million
|
|
£
million
|
|
£
million
|
|
£
million
|
|
£
million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1st April
2024
|
|
|
115
|
|
35
|
|
(6)
|
|
2
|
|
(10)
|
|
(19)
|
|
117
|
|
|
Current service cost -
in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
operating
profit
|
|
|
-
|
|
(9)
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(9)
|
|
|
Administrative expenses -
in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
operating
profit
|
|
|
(2)
|
|
-
|
|
-
|
|
(1)
|
|
-
|
|
-
|
|
(3)
|
|
|
Interest
|
|
|
3
|
|
1
|
|
-
|
|
-
|
|
-
|
|
-
|
|
4
|
|
|
Remeasurements
|
|
|
21
|
|
4
|
|
-
|
|
(4)
|
|
-
|
|
-
|
|
21
|
|
|
Company contributions
|
|
|
-
|
|
12
|
|
-
|
|
1
|
|
-
|
|
-
|
|
13
|
|
|
Exchange
|
|
|
-
|
|
-
|
|
-
|
|
1
|
|
-
|
|
-
|
|
1
|
|
|
At 30th September 2024
|
|
|
137
|
|
43
|
|
(6)
|
|
(1)
|
|
(10)
|
|
(19)
|
|
144
|
|
12
|
Post-employment benefits (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial information (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The post-employment benefit assets
and liabilities are included in the balance sheet as
follows:
|
|
|
|
|
|
|
|
|
|
30.9.24
|
|
30.9.24
|
|
31.3.24
|
|
31.3.24
|
|
|
|
|
|
|
|
|
|
Post-
|
|
|
|
Post-
|
|
|
|
|
|
|
|
|
|
|
|
employment
|
|
Employee
|
|
employment
|
|
Employee
|
|
|
|
|
|
|
|
|
|
benefit
|
|
benefit net
|
|
benefit
|
|
benefit net
|
|
|
|
|
|
|
|
|
|
net
assets
|
|
obligations
|
|
net
assets
|
|
obligations
|
|
|
|
|
|
|
|
|
|
£
million
|
|
£
million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UK pension - legacy
section
|
|
|
|
137
|
|
-
|
|
115
|
|
-
|
|
|
UK pension - cash balance
section
|
|
|
|
43
|
|
-
|
|
35
|
|
-
|
|
|
UK post-retirement medical
benefits
|
|
|
|
-
|
|
(6)
|
|
-
|
|
(6)
|
|
|
US pensions
|
|
|
|
-
|
|
(1)
|
|
2
|
|
-
|
|
|
US post-retirement medical
benefits
|
|
|
|
-
|
|
(10)
|
|
-
|
|
(10)
|
|
|
Other
|
|
|
|
2
|
|
(21)
|
|
1
|
|
(20)
|
|
|
Total post-employment plans
|
|
|
|
182
|
|
(38)
|
|
153
|
|
(36)
|
|
|
Other long-term employee
benefits
|
|
|
|
|
|
(3)
|
|
|
|
(3)
|
|
|
Total long-term employee benefit
obligations
|
|
|
|
(41)
|
|
|
|
(39)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value hierarchy
Fair values are measured using a
hierarchy where the inputs are:
·
Level 1 ─ quoted prices in active markets for
identical assets or liabilities.
·
Level 2 ─ not level 1 but are observable for that
asset or liability either directly or indirectly.
·
Level 3 ─ not based on observable market data
(unobservable).
Fair value of financial instruments
Certain of the group's financial
instruments are held at fair value. The fair value of a financial
instrument is the price that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between
market participants at the balance sheet date.
The fair value of forward foreign
exchange contracts, interest rate swaps, forward precious metal
price contracts and currency swaps is estimated by discounting the
future contractual cash flows using forward exchange rates,
interest rates and prices at the balance sheet date.
The fair value of trade and other
receivables measured at fair value is the face value of the
receivable less the estimated costs of converting the receivable
into cash.
The fair value of money market
funds is calculated by multiplying the net asset value per share by
the investment held at the balance sheet date.
There were no transfers of any
financial instrument between the levels of the fair value hierarchy
during the current or prior periods.
13
|
Fair values (continued)
|
|
|
|
|
|
|
|
|
|
|
|
Fair
value
|
|
|
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
hierarchy
|
|
|
|
|
|
|
|
£ million
|
|
£
million
|
|
level
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial instruments measured at fair
value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current
|
|
|
|
|
|
|
|
|
|
|
|
Investments at fair value through
other comprehensive income1
|
|
40
|
|
40
|
|
1
|
|
Cross currency and interest rate
swaps - assets
|
-
|
|
15
|
|
2
|
|
Other financial
assets2
|
|
|
|
18
|
|
34
|
|
2
|
|
Cross currency and interest rate
swaps - liabilities
|
(10)
|
|
(10)
|
|
2
|
|
Borrowings and related
swaps
|
|
|
-
|
|
(3)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
|
|
Trade
receivables3
|
156
|
|
178
|
|
2
|
|
Other
receivables4
|
|
1
|
|
3
|
|
2
|
|
Cash and cash equivalents - money
market funds
|
456
|
|
334
|
|
2
|
|
Cash and cash equivalents - cash
and deposits
|
5
|
|
12
|
|
2
|
|
Cross currency and interest rate
swaps
|
10
|
|
-
|
|
2
|
|
Other financial
assets2
|
|
|
|
|
49
|
|
53
|
|
2
|
|
Other financial
liabilities2
|
|
|
|
|
(21)
|
|
(11)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair
value
|
|
|
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
hierarchy
|
|
|
|
|
|
|
|
£ million
|
|
£
million
|
|
level
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial instruments not measured at fair
value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current
|
|
|
|
|
|
|
|
Borrowings and related
swaps
|
(1,100)
|
|
(1,336)
|
|
-
|
|
Lease liabilities
|
|
|
|
|
(27)
|
|
(24)
|
|
-
|
|
Other receivables
|
|
|
|
55
|
|
60
|
|
-
|
|
Trade and other
payables
|
|
|
|
|
|
(2)
|
|
(2)
|
|
-
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
|
Amounts receivable under precious
metal sale and repurchase agreements
|
358
|
|
398
|
|
-
|
|
Amounts payable under precious
metal sale and repurchase agreements
|
(719)
|
|
(797)
|
|
-
|
|
Cash and cash equivalents - cash
and deposits
|
160
|
|
196
|
|
-
|
|
Cash and cash equivalents - bank
overdrafts
|
(15)
|
|
(12)
|
|
-
|
|
Borrowings and related
swaps
|
(254)
|
|
(110)
|
|
-
|
|
Lease liabilities
|
|
(8)
|
|
(8)
|
|
-
|
|
Trade and other
receivables
|
833
|
|
926
|
|
-
|
|
Trade and other
payables
|
(1,210)
|
|
(1,235)
|
|
-
|
|
|
|
|
|
|
|
|
1 Investments at fair value through other comprehensive income
are quoted bonds purchased to fund pension deficit (£36 million)
and an investment held at fair value through other comprehensive
income (£4 million).
|
|
|
2 Other financial assets includes forward foreign exchange
contracts (£14 million), forward precious metal price contracts
(£51 million) and currency swaps (£2 million). Other financial
liabilities includes forward foreign exchange contracts (£7
million) and currency swaps (£14 million).
|
|
|
3 Trade receivables held in a part of the group with a business
model to hold trade receivables for collection or sale. The
remainder of the group operates a hold to collect business model
and receives the face value, plus relevant interest, of its trade
receivables from the counterparty without otherwise exchanging or
disposing of such instruments.
|
|
|
|
4 Other receivables with cash flows that do not represent
solely the payment of principal and interest.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|
Fair values (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The fair value of financial
instruments, excluding accrued interest, is approximately equal to
book value except for:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
|
|
|
|
|
Carrying
|
|
Fair
|
|
Carrying
|
|
Fair
|
|
|
|
|
|
amount
|
|
value
|
|
amount
|
|
value
|
|
|
|
|
|
£ million
|
|
£ million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US Dollar Bonds 2025, 2027, 2028,
2029 and 2030
|
(477)
|
|
(455)
|
|
(507)
|
|
(474)
|
|
|
Euro Bonds 2025, 2028, 2030 and
2032
|
(340)
|
|
(319)
|
|
(348)
|
|
(320)
|
|
|
Sterling Bonds 2024, 2025 and
2029
|
(80)
|
|
(74)
|
|
(145)
|
|
(137)
|
|
|
KfW US Dollar Loan 2024
|
(37)
|
|
(37)
|
|
(40)
|
|
(38)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The fair values are calculated
using level 2 inputs by discounting future cash flows to net
present values using appropriate market interest rates prevailing
at the period end.
At
30th September 2024, precious metal leases
were £197 million at closing prices (31st March 2024:
£197 million). Precious metal leases do not fall under the
scope of IFRS 16.
|
|
|
15
|
Transactions with related parties
|
|
|
|
|
There have been no material
changes in related party relationships in the six months ended
30th September 2024. During the half year ended
30th September 2024, the group had sales with associates
totalling £2 million (1H 2023/24: £11 million). The amounts owed by
Veranova were £1 million at 30th September 2024 (1H
2023/24: £nil). No other related party transactions have occurred
which have materially affected the financial position or
performance of the group during the period.
|
|
|
16
|
Contingent liabilities
|
|
|
|
|
The group is involved in various
disputes and claims which arise from time to time in the course of
its business including, for example, in relation to commercial
matters, product quality or liability, employee matters and tax
audits. The group is also involved from time to time in the course
of its business in legal proceedings and actions, engagement with
regulatory authorities and in dispute resolution processes. These
are reviewed on a regular basis and, where possible, an estimate is
made of the potential financial impact on the group. In appropriate
cases a provision is recognised based on advice, best estimates and
management judgement. Where it is too early to determine the likely
outcome of these matters, no provision is made. Whilst the group
cannot predict the outcome of any current or future such matters
with any certainty, it currently believes the likelihood of any
material liabilities to be low, and that such liabilities, if any,
will not have a material adverse effect on its consolidated income,
financial position or cash flows.
Following the sale of its Health
business in May 2022, the purchaser of the Health business,
Veranova Bidco LP, has issued a claim against the group in
connection with: i) certain alleged representations said to have
been made during the course of the negotiation of the sale and
purchase agreement dated 16th December 2021 ("SPA");
and, ii) certain warranties given in the SPA at the time of
signing. Having reviewed the claim with its advisers, the group is
of the opinion that it has a defensible position in respect of
these allegations and is vigorously defending its position. The
outcome of the legal proceedings relating to this matter is not
certain, since the issues of liability and quantum will be for
determination by the court at trial. Accordingly, the group is
unable to make a reliable estimate of the possible financial impact
at this stage, if any.
The group uses various measures to
manage its business which are not defined by generally accepted
accounting principles (GAAP). The group's management believes these
measures provide valuable additional information to users of the
accounts in understanding the group's performance. Certain of these
measures are financial Key Performance Indicators which measure
progress against our strategy.
All non-GAAP measures are on a
continuing operations basis.
17
|
Non-GAAP measures (continued)
|
|
|
|
|
Definitions
Measure
|
Definition
|
Purpose
|
Sales1
|
Revenue excluding sales of precious
metals to customers and the precious metal content of products sold
to customers.
|
Provides a better measure of the
growth of the group as revenue can be heavily distorted by year on
year fluctuations in the market prices of precious metals and, in
many cases, the value of precious metals is passed directly on to
customers.
|
Underlying operating
profit2
|
Operating profit excluding
non-underlying items.
|
Provides a measure of operating
profitability that is comparable over time.
|
Underlying operating profit
margin1,2
|
Underlying operating profit divided
by sales.
|
Provides a measure of how we
convert our sales into underlying operating profit and the
efficiency of our business.
|
Underlying profit before
tax2
|
Profit before tax excluding
non-underlying items.
|
Provides a measure of profitability
that is comparable over time.
|
Underlying profit for the
year2
|
Profit for the year excluding
non-underlying items and related tax effects.
|
Provides a measure of profitability
that is comparable over time.
|
Underlying earnings per
share1,2
|
Underlying profit for the year
divided by the weighted average number of shares in
issue.
|
Our principal measure used to
assess the overall profitability of the group.
|
Return on capital employed
(ROCE)1,3
|
Annualised underlying operating
profit divided by the average equity plus average net debt. The
average is calculated using the opening balance for the financial
year and the closing balance.
|
Provides a measure of the group's
efficiency in allocating the capital under its control to
profitable investments.
|
Average working capital days
(excluding precious metals)1
|
Monthly average of non-precious
metal related inventories, trade and other receivables and trade
and other payables (including any classified as held for sale)
divided by sales for the last three months multiplied by 90
days.
|
Provides a measure of efficiency in
the business with lower days driving higher returns and a healthier
liquidity position for the group.
|
Free cash flow
|
Net cash flow from operating
activities after net interest paid, net purchases of non-current
assets and investments, proceeds from disposal of businesses,
dividends received from joint ventures and associates and the
principal element of lease payments.
|
Provides a measure of the cash the
group generates through its operations, less capital
expenditure.
|
Net debt (including post tax
pension deficits) to underlying EBITDA
|
Net debt, including post tax
pension deficits and quoted bonds purchased to fund the UK pension
(excluded when the UK pension plan is in surplus) divided by
underlying EBITDA for the same period.
|
Provides a measure of the group's
ability to repay its debt. The group has a long-term target of net
debt (including post tax pension deficits) to underlying EBITDA of
between 1.5 and 2.0 times, although in any given year it may fall
outside this range depending on future plans.
|
1 Key Performance Indicator.
2 Underlying profit measures are before profit or loss on
disposal of businesses, amortisation of acquired intangibles, major
impairment and restructuring charges, share of profits or losses
from non-strategic equity investments and, where relevant, related
tax effects. These items have been excluded by management as they
are not deemed to be relevant to an understanding of the underlying
performance of the business.
3 Return on capital employed is a new key performance indicator
in the half year accounts. This was included as a performance
measure in the 2024 Performance Share Plan award. Inclusion of this
measure incentives delivery of the transformation programme across
JM and aligns with investor focus on our ability to return value on
investments.
17
|
Non-GAAP measures (continued)
|
|
|
|
|
|
|
Reconciliations to GAAP measures
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales
|
|
|
|
|
|
|
See note 2.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying profit
measures
|
|
|
|
|
|
|
|
Operating
|
Profit
|
Tax
|
Profit for
|
|
|
|
profit
|
before tax
|
expense
|
the period
|
|
|
Six months ended 30th September
2024
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
Underlying
|
156
|
133
|
(29)
|
104
|
|
|
Amortisation of acquired
intangibles
|
(2)
|
(2)
|
-
|
(2)
|
|
|
Profit on disposal of
businesses1
|
484
|
484
|
(70)
|
414
|
|
|
Major impairment and restructuring
charges1
|
(63)
|
(63)
|
15
|
(48)
|
|
|
Share of profits of
associates
|
-
|
2
|
-
|
2
|
|
|
Change in non-underlying tax
provisions
|
-
|
-
|
14
|
14
|
|
|
Reported
|
575
|
554
|
(70)
|
484
|
|
|
|
|
|
|
|
|
|
1 For further detail please see note 4.
|
|
|
|
|
|
|
|
|
|
|
Operating
|
Profit
|
Tax
|
Profit
for
|
|
|
|
profit
|
before
tax
|
expense
|
the
period
|
|
|
Six months ended 30th September
2023
|
£
million
|
£
million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
Underlying
|
180
|
139
|
(31)
|
108
|
|
|
Amortisation of acquired
intangibles
|
(2)
|
(2)
|
-
|
(2)
|
|
|
Profit on disposal of
businesses
|
-
|
-
|
(3)
|
(3)
|
|
|
Major impairment and restructuring
charges
|
(42)
|
(42)
|
13
|
(29)
|
|
|
Share of losses of
associates
|
-
|
(13)
|
2
|
(11)
|
|
|
Reported
|
136
|
82
|
(19)
|
63
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying earnings per
share
|
|
|
Six months
ended
|
|
|
|
|
|
30.9.24
|
30.9.23
|
|
|
|
|
|
|
|
|
|
Underlying profit for the period
(£ million)
|
|
|
104
|
108
|
|
|
Weighted average number of shares
in issue (million)
|
|
|
181.7
|
183.2
|
|
|
Underlying earnings per share
(pence)
|
|
|
57.4
|
59.1
|
|
|
|
|
|
|
|
|
|
|
|
|
17
|
Non-GAAP measures (continued)
|
|
|
|
|
|
|
Return on Capital Employed
(ROCE)
|
|
|
|
|
|
|
|
|
|
|
|
Six months
|
|
Year
|
|
Six
months
|
|
|
|
|
ended
|
|
ended
|
|
ended
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
30.9.23
|
|
|
|
|
£
million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
Underlying operating profit for
this period
|
|
|
156
|
|
410
|
|
180
|
|
Underlying operating profit for
prior year
|
|
|
410
|
|
-
|
|
465
|
|
Less: Underlying operating profit
for prior first half
|
|
|
(180)
|
|
-
|
|
(222)
|
|
Annualised underlying operating profit
|
|
|
386
|
|
410
|
|
423
|
|
|
|
|
|
|
|
|
|
|
Average net debt
|
|
|
867
|
|
987
|
|
1,034
|
|
Average equity
|
|
|
2,400
|
|
2,459
|
|
2,486
|
|
Average capital employed
|
|
|
3,267
|
|
3,446
|
|
3,520
|
|
|
|
|
|
|
|
|
|
|
ROCE
|
|
|
11.8%
|
|
11.9%
|
|
12.0%
|
|
|
|
|
|
|
|
|
|
|
Average working capital days
(excluding precious metals)
|
|
|
Six months
|
|
Year
|
|
Six
months
|
|
|
|
|
ended
|
|
ended
|
|
ended
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
30.9.23
|
|
|
|
|
£
million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
|
1,153
|
|
1,211
|
|
1,517
|
|
Trade and other
receivables
|
|
|
1,588
|
|
1,718
|
|
1,759
|
|
Trade and other
payables
|
|
|
(2,070)
|
|
(2,209)
|
|
(2,263)
|
|
|
|
|
671
|
|
720
|
|
1,013
|
|
Working capital balances
classified as held for sale
|
|
|
-
|
|
44
|
|
-
|
|
Total working capital
|
|
|
671
|
|
764
|
|
1,013
|
|
Less: Precious metal working
capital
|
|
|
(163)
|
|
(174)
|
|
(371)
|
|
Working capital (excluding precious metals)
|
|
|
508
|
|
590
|
|
642
|
|
|
|
|
|
|
|
|
|
|
Average working capital days (excluding precious
metals)
|
|
|
57
|
|
60
|
|
57
|
|
|
|
|
|
|
|
|
|
|
Free cash
flow
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months
ended
|
|
|
|
|
|
|
30.9.24
|
|
30.9.23
|
|
|
|
|
|
|
£
million
|
|
£
million
|
|
Net cash (outflow) / inflow from
operating activities
|
|
|
|
|
(22)
|
|
236
|
|
Interest received
|
|
|
|
|
44
|
|
19
|
|
Interest paid
|
|
|
|
|
(77)
|
|
(53)
|
|
Purchases of property, plant and
equipment
|
|
|
|
|
(150)
|
|
(125)
|
|
Purchases of intangible
assets
|
|
|
|
|
(21)
|
|
(33)
|
|
Government grant income
|
|
|
|
|
-
|
|
1
|
|
Proceeds from sale of
businesses
|
|
|
|
|
578
|
|
39
|
|
Principal element of lease
payments
|
|
|
|
|
(5)
|
|
(6)
|
|
Free cash flow
|
|
|
|
|
347
|
|
78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17
|
Non-GAAP measures (continued)
|
|
|
|
|
|
|
Net debt (including post tax
pension deficits) to underlying EBITDA
|
|
|
|
|
|
|
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
30.9.23
|
|
|
|
|
|
£
million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and deposits
|
|
|
165
|
|
208
|
|
193
|
|
|
Money market funds
|
|
|
456
|
|
334
|
|
300
|
|
|
Bank overdrafts
|
|
|
(15)
|
|
(12)
|
|
(31)
|
|
|
Cash and cash equivalents
|
|
|
606
|
|
530
|
|
462
|
|
|
Cross currency and interest rate
swaps - current assets
|
|
|
10
|
|
-
|
|
-
|
|
|
Cross currency and interest rate
swaps - non-current assets
|
|
|
-
|
|
15
|
|
19
|
|
|
Cross currency and interest rate
swaps - non-current liabilities
|
|
|
(10)
|
|
(10)
|
|
(16)
|
|
|
Borrowings and related swaps -
current
|
|
|
(254)
|
|
(110)
|
|
(71)
|
|
|
Borrowings and related swaps -
non-current
|
|
|
(1,100)
|
|
(1,339)
|
|
(1,398)
|
|
|
Lease liabilities -
current
|
|
|
(8)
|
|
(8)
|
|
(9)
|
|
|
Lease liabilities -
non-current
|
|
|
(27)
|
|
(24)
|
|
(31)
|
|
|
Lease liabilities - current -
transferred to liabilities classified as held for sale
|
|
|
-
|
|
(1)
|
|
-
|
|
|
Lease liabilities - non-current -
transferred to liabilities classified as held for sale
|
|
|
-
|
|
(4)
|
|
-
|
|
|
Net debt
|
|
|
(783)
|
|
(951)
|
|
(1,044)
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase / (decrease) in cash and
cash equivalents
|
|
|
76
|
|
(102)
|
|
(172)
|
|
|
Less: Decrease in
borrowings
|
|
|
47
|
|
150
|
|
149
|
|
|
Less: Principal element of lease
payments
|
|
|
5
|
|
11
|
|
6
|
|
|
Decrease / (increase) in net debt resulting from cash
flows
|
|
|
128
|
|
59
|
|
(17)
|
|
|
New leases, remeasurements and
modifications
|
|
|
(9)
|
|
(11)
|
|
(7)
|
|
|
Other lease movements
|
|
(3)
|
|
1
|
|
-
|
|
|
Disposal of businesses
|
|
|
5
|
|
11
|
|
10
|
|
|
Exchange differences on net
debt
|
|
|
43
|
|
13
|
|
2
|
|
|
Other non-cash
movements
|
|
|
4
|
|
(1)
|
|
(9)
|
|
|
Movement in net debt
|
|
|
168
|
|
72
|
|
(21)
|
|
|
Net debt at beginning of
year
|
|
|
(951)
|
|
(1,023)
|
|
(1,023)
|
|
|
Net debt at end of year
|
|
|
(783)
|
|
(951)
|
|
(1,044)
|
|
|
|
|
|
|
|
|
|
|
|
|
Net debt
|
|
|
(783)
|
|
(951)
|
|
(1,044)
|
|
|
Add: Pension deficits
|
|
|
(22)
|
|
(22)
|
|
(21)
|
|
|
Add: Related deferred
tax
|
|
|
3
|
|
3
|
|
3
|
|
|
Net debt (including post tax pension
deficits)
|
|
|
(802)
|
|
(970)
|
|
(1,062)
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying EBITDA for this
period
|
|
|
250
|
|
|
|
273
|
|
|
Underlying EBITDA for prior
year
|
|
|
598
|
|
|
|
647
|
|
|
Less: Underlying EBITDA for prior
half year
|
|
|
(273)
|
|
|
|
(309)
|
|
|
Annualised underlying EBITDA
|
|
|
575
|
|
598
|
|
611
|
|
|
|
|
|
|
|
|
|
|
|
|
Net debt (including post tax pension deficits) to underlying
EBITDA
|
1.4
|
|
1.6
|
|
1.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17
|
Non-GAAP measures (continued)
|
|
|
|
|
|
|
|
|
|
30.9.24
|
|
31.3.24
|
|
30.9.23
|
|
|
|
|
|
£
million
|
|
£
million
|
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying EBITDA
|
|
|
250
|
|
598
|
|
273
|
|
|
Depreciation and
amortisation
|
|
|
(96)
|
|
(192)
|
|
(95)
|
|
|
Profit / (loss) on disposal of
businesses
|
|
|
484
|
|
(9)
|
|
-
|
|
|
Major impairment and restructuring
charges
|
|
|
(63)
|
|
(148)
|
|
(42)
|
|
|
Finance costs
|
|
|
(72)
|
|
(146)
|
|
(71)
|
|
|
Finance income
|
|
|
49
|
|
64
|
|
30
|
|
|
Share of profits / (losses) of
associates
|
|
|
2
|
|
(3)
|
|
(13)
|
|
|
Income tax expense
|
|
|
(70)
|
|
(56)
|
|
(19)
|
|
|
Profit for the period
|
|
|
484
|
|
108
|
|
63
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|